GlassScriptPhysician profile
Bijan Ahrari
NPI 1679726467
$46,769.34
in general payments reported to CMS, 2019-2025
51 companies · $13K in 2025
The $13K reported for 2025 was more than what 91% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,320 · 2020: $2,235 · 2021: $7,704 · 2022: $11K · 2023: $2,456 · 2024: $2,475 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,181 · Food and Beverage: $7,408 · Travel and Lodging: $1,678 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,180.50 |
| Food and Beverage | $7,407.56 |
| Travel and Lodging | $1,678.38 |
| Education | $114.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $21,746.13 | 2019-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $10,198.86 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,855.48 | 2019-2020 | |
| Eli Lilly and Company | $1,694.38 | 2025 | |
| Novo Nordisk INC | $1,514.25 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,078.24 | 2019-2025 | Repatha, Evenity, Tepezza |
| Abbott Laboratories | $950.28 | 2019-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $600.43 | 2019-2021 | |
| Dexcom, INC. | $542.32 | 2019-2023 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $387.89 | 2022-2024 | Recorlev, Gvoke Hypopen |
| Chiesi USA, INC. | $381.82 | 2024 | Myalept, Mycapssa |
| Recordati_rare_diseases_inc. | $377.68 | 2023-2025 | Isturisa, Signifor Lar |
| Lilly USA, LLC | $374.42 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $373.23 | 2019-2025 | Jardiance |
| Neurocrine Biosciences, INC. | $353.63 | 2024-2025 |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $324.66 | 2019-2025 | |
| Horizon Therapeutics Plc | $308.92 | 2020-2023 | Tepezza |
| Madrigal Pharmaceuticals | $300.42 | 2024-2025 | Rezdiffra, Resmetirom |
| Bayer Healthcare Pharmaceuticals INC. | $283.93 | 2021-2023 | |
| Tandem Diabetes Care, INC. | $237.85 | 2020-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Kyowa Kirin, INC. | $204.91 | 2023-2025 | Crysvita |
| Insulet Corporation | $204.81 | 2020-2025 | Omnipod |
| Alexion Pharmaceuticals, INC. | $185.07 | 2019-2023 | |
| Ascensia Diabetes Care US INC. | $184.17 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $173.11 | 2019-2020 | |
| Mannkind Corporation | $168.42 | 2019-2025 | |
| Amarin Pharma, INC. | $153.85 | 2019-2022 | |
| Averitas Pharma INC. | $139.99 | 2025 | Qutenza |
| Beta Bionics, INC. | $133.07 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ascendis Pharma Endocrinology INC | $125.25 | 2025 | Yorvipath |
| Esperion Therapeutics, INC. | $123.47 | 2022-2024 | Nexletol |
| Ipsen Biopharmaceuticals, INC | $116.81 | 2019 | |
| Ibsa Pharma INC. | $114.75 | 2020-2025 | Tirosint, Licart, Flector |
| Shire North American Group INC | $95.44 | 2019 | |
| Biomarin Pharmaceutical INC. | $95.13 | 2022 | |
| Pfizer INC. | $90.08 | 2023-2024 | |
| Radius Health, INC. | $75.73 | 2020-2023 | Tymlos |
| Novartis Pharmaceuticals Corporation | $64.79 | 2023-2025 | |
| Amryt Pharma Holdings LTD | $51.61 | 2022 | |
| Endo Pharmaceuticals INC. | $50.13 | 2019-2024 | Aveed |
| Soleno Therapeutics, INC. | $48.16 | 2025 | Vykat Xr |
| Lifescan, INC. | $41.04 | 2020 | |
| Antares Pharma, INC. | $41.04 | 2019-2020 | |
| Boston Scientific Corporation | $39.59 | 2020-2025 | General - Pain Management |
| Mylan Specialty L.P. | $33.60 | 2023 | |
| Aytu Biopharma, INC. | $30.19 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $23.37 | 2024 | |
| Eisai INC. | $21.21 | 2019 | |
| Medtronic, INC. | $20.84 | 2023 | Minimed 780g |
| Sequel Med Tech, LLC | $19.79 | 2025 | Twiist |
| Almatica Pharma LLC | $15.10 | 2025 | Teriparatide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bijan Ahrari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.